Detection of Post-Translationally Modified Proteins as a Biomarker Panel for Parkinson's Disease (U01)
This project will use Single Molecular Array (SiMoA) technology to develop digital bead-based ELISA assays to detect post-translational modifications of key proteins relevant to Lewy body pathology including, but not limited to: ubiquitinated phospho-serine alpha synuclein; 4-HNE modified DJ-1; phospho-tau isoforms and alpha-synuclein bound to tau; anti-melanin antibodies; oligomeric alpha-synuclein and cytokines including IL-6 and IL-8. PDBP serum samples from healthy controls, Parkinson’s disease patients and other Parkinsonisms will be used in these assays. Results from these assays will guide development of a multiplex assay(s), as well as the development of a multivariate predictive statistical model for PD status.
Program Director/Principal Investigator (Walt, David, R): Project Abstract To date, research aimed at identifying a biomarker for Parkinson's Disease (PD) has, for the most part, focused on measuring the levels of all isoforms of a given protein such as alpha-synuclein or DJ-1 in serum or CSF. These methods, however, have not had the sensitivity and specificity necessary to be used as an indicator of disease. Recent evidence suggests that specific post-translational modifications such as phosphorylation and ubiquitination are key to the pathophysiology of PD. These post-translationally modified proteins have not yet been measured in serum because the concentrations of these isoforms are likely below the limit of detection of conventional ELISAs. We hypothesize that the detection of post-translationally modified proteins will be critical to PD biomarker development. Therefore, we will use technology, newly developed in our lab, which is 100-1000 times more sensitive than traditional ELISA to detect these isoforms. This new technology, Single Molecule Arrays (SiMoA), is a digital ELISA that counts individual molecules in solution. This proposal seeks to develop SiMoAs specific for post-translationally modified proteins relevant to PD. We will create a simple blood test and assess its sensitivity and specificity using serum samples from PD patients, healthy controls and individuals with other movement disorders provided by the PDBP. In sum, this application seeks to create a biomarker panel that is sensitive, specific, noninvasive and substantially cheaper than current diagnostic methods.
Goals of this project:
1. Develop 6-10 SiMoA assays to detect and quantify post-translationally-modified proteins in serum or plasma that are associated with Parkinson’s disease pathology, genetics, or neuro-inflammatory responses and test their sensitivity and specificity using samples from PDBP PD patients and healthy controls.
2. Work towards a multiplex assay for the individual SiMoA assays that meet sensitivity and specificity criteria.